![Renejix CDMO Partner for Small Molecule Oral Dosage Forms](https://www.pharmacompass.com/image/flap/renejix-w35-desktop-header-01gif-33629.gif)
![Renejix CDMO Partner for Small Molecule Oral Dosage Forms](https://www.pharmacompass.com/image/flap/renejix-w35-mob-header-01gif-17728.gif)
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Details:
The grant will support preclinical research of Kannalife’s KLS-13019 by investigating its effects on neuroinflammation and mitochondrial dysfunction, which are implicated in Parkinson’s disease.
Lead Product(s): KLS-13019
Therapeutic Area: Neurology Product Name: KLS-13019
Highest Development Status: PreclinicalProduct Type: Small molecule
Partner/Sponsor/Collaborator: The Michael J. Fox Foundation
Deal Size: $1.4 million Upfront Cash: Undisclosed
Deal Type: Funding June 25, 2024
Details:
With the PCT Patent, along with Kannalife’s novel lead drug candidate, KLS-13019, and its other novel therapeutic agents like Atopidine™, Kannalife now has near global coverage in the top pharmaceutical markets in the world.
Lead Product(s): KLS-13019
Therapeutic Area: Neurology Product Name: KLS-13019
Highest Development Status: PreclinicalProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable August 25, 2020
Details:
In comparison with CBD and morphine, KLS-13019 stood out as a viable drug candidate that out-performed CBD and poses as a viable alternative to the use of opioids.
Lead Product(s): KLS-13019
Therapeutic Area: Neurology Product Name: Undisclosed
Highest Development Status: Phase IProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable January 14, 2020